# Tuberculosis Treatment Shortening Trial

> **NCT00130247** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 394 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Ethambutol
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT00130247
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04-08
- **Primary completion:** 2008-09-02
- **Final completion:** 2008-11-28
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130247, "Tuberculosis Treatment Shortening Trial". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00130247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*